A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumors

被引：6
|
作者：
Bauer, S. [1 ]
Demetri, G. [2 ]
Jeay, S. [3 ]
Dummer, R. [4 ]
Guerreiro, N. [3 ]
Tan, D. S. [5 ]
Kumar, A. [6 ]
Meille, C. [3 ]
Van Bree, L. [3 ]
Halilovic, E. [7 ]
Wuerthner, J. U. [3 ]
Cassier, P. [8 ]
机构：
[1] Univ Klinikum Essen, Internal Med, Essen, Germany
[2] Dana Farber Canc Inst, Ludwig Ctr, Boston, MA 02115 USA
[3] Novartis Pharma AG, Basel, Switzerland
[4] Univ Zurich Hosp, Zurich, Switzerland
[5] Natl Canc Ctr, Singapore, Singapore
[6] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
[7] Novartis Inst BioMed Res, Cambridge, MA USA
[8] Ctr Leon Berard, Lyon, France
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw368.9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
366PD
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I, multi-center, dose-escalation and dose-expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors
    Lin, C-C.
    Grewal, J.
    Baranda, J. C.
    Schneider, R. E.
    Zhang, J.
    Bai, L-Y.
    Yeh, Y-M.
    Sommerhalder, D.
    Li, G.
    Shen, L.
    Hsu, H-C.
    Alese, O.
    Yin, R.
    Hsieh, C-Y.
    Cai, S. X.
    Tian, Y. E.
    Xia, H.
    Li, B.
    Zhang, M.
    Zhang, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S466 - S466
  • [22] A PHASE IB, MULTI-CENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF ORAL PANOBINOSTAT (LBH589) AND IV BORTEZOMIB IN ADULT PATIENTS WITH MULTIPLE MYELOMA (MM)
    Sezer, O.
    Kaiser, M.
    Siegel, D.
    Prosser, I.
    Mateos, M. V.
    Kangas, M.
    Jalaluddin, M.
    Bourquelot, P.
    Blade, J.
    Miguel, J. San
    Anderson, K.
    Bradner, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 176 - 176
  • [23] A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis
    Verstovsek, Srdan
    Hoffman, Ronald
    Mascarenhas, John
    Soria, Jean-Charles
    Bahleda, Ratislav
    McCoon, Patricia
    Tang, Weifeng
    Cortes, Jorge
    Kantarjian, Hagop
    Ribrag, Vincent
    LEUKEMIA RESEARCH, 2015, 39 (02) : 157 - 163
  • [24] Safety of the Herbal Medicine SH003 in Patients With Solid Cancer: A Multi-Center, Single-Arm, Open-Label, Dose-Escalation Phase I Study
    Cheon, Chunhoo
    Lee, Hyun Woo
    Sym, Sun Jin
    Ko, Seong-Gyu
    INTEGRATIVE CANCER THERAPIES, 2024, 23
  • [25] Phase I dose-escalation, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies.
    De Mattos-Arruda, Leticia
    Siu, Lillian L.
    Cortes, Javier
    Berge, Yann
    Razak, Albiruni R. A.
    Ahnert, Jordi Rodon
    Cottura, Ewa
    Bedard, Philippe
    Akimov, Mikhail
    Lu, Hong
    Pain, Scott
    Kaag, Audrey
    Delord, Jean-Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] A phase Ia/Ib, open label, multicenter, dose -escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors.
    Chong, Curtis Robert
    Bauer, Todd Michael
    Laurie, Scott Andrew
    Patel, Manish R.
    Yamamoto, Noboru
    Davenport, Teffany
    Geng, Junxian
    Gibson, Neil
    Vallaster, Markus P.
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] KontRASt: A Phase Ib/II, open-label, multi-center, dose-escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation
    Solomon, Benjamin
    Heist, Rebecca S.
    Tan, Daniel S. W.
    Cassier, Philippe A.
    Dooms, Christophe
    Van Cutsem, Eric
    Steuer, Conor E.
    Steeghs, Neeltje
    Schuler, Martin
    Gazzah, Anas
    Wermke, Martin
    Felip, Enriqueta
    Loong, Herbert H. F.
    Luken, Maria J. De Miguel
    Soo, Ross A.
    Jaeger, Ashley
    Xu, Kun
    Chen, Xueying
    Cui, Xiaoming
    Burks, Heather
    Farago, Anna F.
    Shimizu, Toshio
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [28] An open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics of oral administration of irinotecan in adult patients with solid tumors
    Palshof, J. A.
    Kumler, I.
    Sorensen, P. G.
    Jensen, B. V.
    Nielsen, D. L.
    ANNALS OF ONCOLOGY, 2018, 29 : 142 - 142
  • [29] A phase 1, multi-center, open-label, dose-escalation, and dose-expansion study of CBP-1018, a bi-ligand-drug conjugate in patients with heavily treated advanced solid tumors.
    Li, Kaiwen
    Wu, Junyan
    Ye, Suiwen
    Liu, Yanqiong
    Huang, Hao
    Fan, Fan
    Lai, Yiming
    Zhuang, Suili
    Zhou, Liyan
    Huang, Robert
    Xu, Mo
    Pan, Bin
    Zhang, Jian
    Shi, Yehui
    Huang, Hai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] A phase I, open-label, dose-escalation study investigating a low-density lipoprotein receptor-related protein (LRP) 5/6 inhibitor, BI 905677, in patients with advanced solid tumors.
    Elez, Elena
    Lenz, Heinz-Josef
    de Jonge, Maja
    Yaeger, Rona
    Doi, Toshihiko
    Pronk, Linda
    Teufel, Michael
    Marzin, Kristell
    Tabernero, Josep
    CANCER RESEARCH, 2022, 82 (12)
12345